Takeda Pharmaceutical Company


The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical and biopharmaceutical company. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo.
In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

History

Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925.
In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals, Takeda and Abbott launched the blockbusters Lupron in 1985 and Prevacid in 1995.
One of the firm's mainstay drugs is Actos, a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. It was launched in 1999.
In February 2005, Takeda acquired San Diego, California, based Syrrx, a company specializing in high-throughput X-ray crystallography, for US$270 million.
In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market. In March 2008, Takeda and Abbott Laboratories announced plans to conclude their 30-year-old joint venture, TAP Pharmaceuticals. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff. On the other hand, Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees. In April 2008, Takeda acquired Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for US$8.8 billion. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary. In May 2008, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.
In September 2011, Takeda acquired Nycomed for €9.6 billion.
In June 2012, Takeda announced it would acquire URL Pharma, then run by the founder's son Richard Roberts, for US$800 million. On 25 May 2012, Takeda purchased Brazilian pharmaceutical company Multilab for R$540 million.
On 26 September 2014, Takeda announced it would team up with BioMotiv to identify and develop new compounds over a five-year period, worth approximately US$25 million. On 30 September 2014, Takeda announced it would expand a collaboration with MacroGenics, valued up to US$1.6 billion. The collaboration focused on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and CD79B, and is indicated for lupus and rheumatoid arthritis.
In 2015, Takeda sold its respiratory drugs business to AstraZeneca for $575 million, which included roflumilast and ciclesonide. On November 20, 2015, the U.S. Food and Drug Administration approved Ixazomib developed by Takeda for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy.
On December 2, 2016, the company spun out its neuroscience research division into Cerevance, a joint venture along with Lightstone Ventures.
In February 2017, Takeda acquired Ariad Pharmaceuticals for $5.2 billion, expanding the company's oncology and hematology divisions.
In January 2018, the company acquired stem cell therapy developer TiGenix for up to €520 million.
In January 2019, Takeda acquired Shire for more than.
In October 2019, Takeda announced it had sold a portfolio of over-the-counter and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino International for more than $200 million.
In March 2020, Takeda announced that it has entered into an exclusively agreement to divest a portfolio of non-core products in Latin America to Hypera S.A. for a total value of $825 million.

Acquisition history

In May 2019, Takeda sold its Xiidra dry-eye drug business to Novartis for $5.3 billion, $3.4 billion upfront and up-to $1.9 billion in sales milestones.
In November 2019, Takeda entered an agreement to sell its over-the-counter and prescription drugs businesses in Russia, Georgia, Armenia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan to Stada Arzneimittel for $660 million.
In June 2020, Takeda announced that it was divesting 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion in a deal worth $278 million.

Locations

Takeda operates two primary bases in Japan in Osaka and Tokyo. Its United States subsidiary is based in Cambridge, Massachusetts, and all Global Operations outside Japan and U.S. are based in Opfikon, Switzerland.
The company maintains research and development sites in Japan, the United States, the United Kingdom and Singapore, with manufacturing facilities across the globe.

Lawsuits

In April 2015 Takeda agreed to pay a settlement of $2.37 billion to an estimated 9,000 people who submitted claims alleging that pioglitazone was responsible for giving them bladder cancer. In 2014, a plaintiff was awarded $9 billion in punitive damages after a federal court found Takeda hid the cancer risks of their diabetes medicine, but the amount was later reduced to $26 million by a judge who deemed the charge excessive.